Amarillo Biosciences, Inc. - AMAR- Profile

Amarillo Biosciences, Inc.. The Group's principal activity is to develop biologics for the treatment of human and animal diseases. The Group is currently in its research on human health indications for the use of low-dose orally administered natural human interferon alpha. This is particularly for the treatment of Sjogren's syndrome, Behcet's disease, polycythemia vera, essential thrombocythemia, idiopathic pulmonary fibrosis and oral warts in HIV+ patients. The Group owns 15 United States patents relating to low-dose oral natural interferon alpha. . In 2005, the clinical protocol was developed, clinical supplies were made and packaged, and clinical investigators identified. On 19-Oct-2005, Group reached agreement with Global Kinetics of Kent, Washington to become the distributor of oral interferon in Cambodia. On 29-Dec-2005 it announced that it had entered into a distribution agreement with Bumimedic (M) Sdn. Royalty revenue accounted for 44% of 2005 revenues, Dietary supplement sales, 28% and Federal research grant, 28%